Cockayne syndrome is a neurodegenerative accelerated aging disorder caused by mutations in the CSA or CSB genes. Although the pathogenesis of Cockayne syndrome has remained elusive, recent work implicates mitochondrial dysfunction in the disease progression. Here, we present evidence that loss of CSA or CSB in a neuroblastoma cell line converges on mitochondrial dysfunction caused by defects in ribosomal DNA transcription and activation of the DNA damage sensor poly-ADP ribose polymerase 1 (PARP1). Indeed, inhibition of ribosomal DNA transcription leads to mitochondrial dysfunction in a number of cell lines. Furthermore, machine-learning algorithms predict that diseases with defects in ribosomal DNA (rDNA) transcription have mitochondrial dysfunction, and, accordingly, this is found when factors involved in rDNA transcription are knocked down. Mechanistically, loss of CSA or CSB leads to polymerase stalling at non-B DNA in a neuroblastoma cell line, in particular at G-quadruplex structures, and recombinant CSB can melt G-quadruplex structures. Indeed, stabilization of G-quadruplex structures activates PARP1 and leads to accelerated aging in Caenorhabditis elegans. In conclusion, this work supports a role for impaired ribosomal DNA transcription in Cockayne syndrome and suggests that transcription-coupled resolution of secondary structures may be a mechanism to repress spurious activation of a DNA damage response.
Cockayne syndrome is a neurodegenerative accelerated aging disorder caused by mutations in the CSA or CSB genes. Although the pathogenesis of Cockayne syndrome has remained elusive, recent work implicates mitochondrial dysfunction in the disease progression.
Here, we present evidence that loss of CSA or CSB in a neuroblastoma cell line converges on mitochondrial dysfunction caused by defects in ribosomal DNA transcription and activation of the DNA damage sensor poly-ADP ribose polymerase 1 (PARP1). Indeed, inhibition of ribosomal DNA transcription leads to mitochondrial dysfunction in a number of cell lines. Furthermore, machine-learning algorithms predict that diseases with defects in ribosomal DNA (rDNA) transcription have mitochondrial dysfunction, and, accordingly, this is found when factors involved in rDNA transcription are knocked down. Mechanistically, loss of CSA or CSB leads to polymerase stalling at non-B DNA in a neuroblastoma cell line, in particular at G-quadruplex structures, and recombinant CSB can melt G-quadruplex structures. Indeed, stabilization of G-quadruplex structures activates PARP1 and leads to accelerated aging in Caenorhabditis elegans. In conclusion, this work supports a role for impaired ribosomal DNA transcription in Cockayne syndrome and suggests that transcription-coupled resolution of secondary structures may be a mechanism to repress spurious activation of a DNA damage response.
Cockayne syndrome | aging | polymerase I transcription | nucleolus | CSA | CSB C ockayne syndrome (CS) is an early onset accelerated aging disorder characterized by growth retardation, progressive neurodegeneration, and typically death in the second decade of life (1, 2) . The disease is caused by mutations in either the ERCC8 (CSA) or ERCC6 (CSB) genes, which encode proteins that are thought to be involved in DNA repair, transcription, and chromatin remodeling (3) (4) (5) . Recent work has demonstrated mitochondrial dysfunction in cell and animal models deficient in CSB (6) (7) (8) (9) (10) . The disease mechanism may involve persistent activation of a DNA damage response orchestrated by the enzyme poly-ADP ribosepolymerase 1 (PARP1) leading to loss of NAD + and increased lactate production (8, 11) , features that are also observed in normal aging (12) (13) (14) . However, it is unclear why PARP1 is activated upon loss of CSB or in normal aging and whether persistent PARP1 activation also occurs in CSA deficiency. Our results support the notion that the mitochondrial changes observed in CSA or CSB deficiency are caused by stalled ribosomal DNA (rDNA) transcription and subsequent PARP1 activation. Accordingly, we find that diseases with defects in rDNA transcription have dysfunctional mitochondria whereas classic ribosomopathies do not appear to have this defect. rDNA is prone to form secondary structures, such as G-quadruplexes (G4), and loss of CSA or CSB leads to transcriptional pausing at these DNA conformations. G4-induced transcriptional stalling is also found in vivo in humans. CSB is able to melt G4 structures in a process that involves annealing the two DNA strands. Furthermore, stabilization of G4 structures leads to PARP1 activation and accelerated aging in Caenorhabditis elegans, which can be rescued by replenishment of NAD + . Combined, our findings suggest a role for CS proteins in transcription and may explain why PARP1 might be activated in this premature aging disorder.
Loss of CSA or CSB Leads to Mitochondrial Dysfunction
To understand why a similar pathology is present in both complementation groups of CS, CSA and CSB, we generated stable knockdown of CSA or CSB in the neuroblastoma cell line SH-SY5Y using lentivirus ( Fig. S1 A and B) . In accordance with our findings for CSB (8) , loss of CSA or CSB led to activation of PARP1 and mitochondrial changes consisting of increased mitochondrial membrane potential, superoxide production, and increased oxygen consumption rates ( Fig. 1 A-D and Fig. S1C ). Increased oxygen consumption rates were also found in C. elegans worms defective in csa-1 or csb-1 (Fig. 1E) . Notably, microarray analysis showed very similar gene expression changes when either CSA or CSB were deficient ( Fig. 1F and Dataset S1). Parametric Analysis of Gene Set Enrichment showed significant up-regulation of Gene Ontology (GO) terms describing genes involved in ribosome biogenesis and translation as well as in mitochondrial ATP production, likely reflecting the observed functional mitochondrial changes (Fig. 1F) . Down-regulated ontology terms included ubiquitin pathways and transcriptional regulation (Fig. 1F) .
Significance
In this paper we describe a possible pathogenesis for the accelerated aging disease Cockayne syndrome that entails defective transcription through DNA secondary structures leading to activation of the DNA damage response enzyme poly-ADP-ribose polymerase 1 and downstream mitochondrial derangement. These findings are important because they signify a possible new role of transcription in the resolution of DNA structures that form spontaneously and suggest a possible pathogenesis for this accelerated aging disease. Given that CSA and CSB have been implicated in transcription driven by RNA polymerases I (15, 16) , II (17) , and III (18), we measured gene expression changes in unmodified SH-SY5Y cells after treatment with specific transcriptional inhibitors compared with controls (RNA polymerase I: CX5461; RNA polymerase I/II: triptolide; RNA polymerase II: α-amanitin; RNA polymerase I/II/ III: actinomycin D; and RNA polymerase III: ML60218). We treated the cells with the inhibitors at several concentrations to avoid data bias that might occur when choosing only one concentration. Additionally, we treated the knockdown cells with the PARP inhibitor PJ34. To validate the results, we included gene expression array data from the cerebellum of human CS patients and their controls from a recently published study (19) . Notably, hierarchical clustering showed an association between the CS patients and the transcription inhibitor treatments, despite batch and tissue differences. Intriguingly, clustering revealed close association between the loss of CSA or CSB and the inhibition of rDNA transcription, and these changes were completely rescued by PARP inhibition (Fig. 1G) . As a positive control, very low concentrations of ML60218 (1 μM) or CX5461 (0.001 μM) led to very few significantly changed GO terms (Fig. 1G) . Indeed, there was no association between these two treatments and CSA or CSB knockdown in the hierarchical clustering (Fig. 1G) . In summary, these data suggest that CSA and CSB deficiency leads to decreased rDNA transcription.
To address this hypothesis, rDNA transcription was measured and found to be lower in short hairpin (sh)CSA and shCSB cell lines, as demonstrated by the loss of 47S pre-rRNA by RT-qPCR as well as by loss of nucleolar ethynyl uridine (EU) incorporation ( Fig. 1 H and I and Fig. S1D ). Loss of rDNA transcription was also found in fibroblasts from CSA-and from CSB-deficient patients compared with isogenic controls transfected with wild-type (WT) CSA or CSB (Fig. S1 E-G) . Because microarray analysis showed up-regulation of genes involved in translation and mitochondrial pathways, we postulate that this outcome reflects compensation due to loss of rDNA transcription. Indeed, inhibition of rDNA transcription using CX5461 led to a significant increase in mitochondrial membrane potential, content (by mitotracker green staining), and superoxide production ( Fig. 1J and Fig. S1 H and I). Furthermore, there was no additive effect between loss of CSA or CSB and the CX5461 treatment, suggesting that the mitochondrial signaling comes from the same pathway ( Fig. 1J and Fig. S1 H and I). In summary, loss of rDNA transcription may be driving mitochondrial changes in CS.
Loss of rDNA Transcription Leads to Mitochondrial Dysfunction
We next asked whether inhibition of transcription produced a mitochondrial response across different cell lines. We treated SH-SY5Y, HeLa (WT and PARP1 null), HEK293T, WI38, primary MEFs, U2OS, and HCT116 (WT and p53 null) with different concentrations of inhibitors of RNA polymerase I (CX-5461 and triptolide), II (α-amanitin and triptolide), or III (ML-60218) and measured mitochondrial changes. Interestingly, RNA polymerase I inhibition led to a mitochondrial phenotype similar to what is seen in CS, with significantly increased mitochondrial membrane potential, content, and mitochondrial superoxide production in all cell lines tested ( Fig ) showed a significantly attenuated response to RNA polymerase I inhibition compared with the parental HeLa cell line ( Fig. 2A) . To further test whether these changes depended on PARP1 activation, we treated HeLa cells with RNA polymerase I inhibitor alone or in combination with the PARP1 inhibitor PJ34. As shown, the mitochondrial changes that are caused by inhibition of RNA polymerase I were completely reversed by treatment with PJ34 ( Fig. 2B and Fig. S2 B-D) . To test the effect of the inhibitors at an organismal level independent of CS, C. elegans were treated with RNA polymerase I, II, or III inhibitors and examined for mitochondrial changes. In agreement with the cellular data, RNA polymerase inhibitors increased oxygen consumption rates, with RNA polymerase I inhibition having the greatest effect (Fig. 2C) .
Thus, there appears to be a direct link between transcriptional efficiency, particularly of rDNA, and mitochondrial function.
Ribosomal Defects Do Not Cause Mitochondrial Dysfunction
A number of diseases have been described with defects in rDNA transcription [spinocerebellar ataxia 17 (SCA17) and hypomyelinating leukodystrophy 7 (HLD7)], pre-rRNA processing [North American Indian Childhood Cirrhosis (NAIC) and Treacher Colins syndrome (TCOF)], and ribosome assembly [DiamondBlackfan anemia (DBA)] (20) (21) (22) (23) (24) (25) . To understand the mechanism of how transcriptional defects generate mitochondrial changes, we used our recently developed in silico algorithms to predict mitochondrial involvement in the above-listed disorders based on clinical features (11, 26) . Considering the clinical spectrum of these diseases, hierarchical clustering showed an association between defects in rDNA transcription (SCA17 and HLD7) and mitochondrial disorders, whereas NAIC, TCOF, and DBA did not show this relationship (Fig. 2D) . A network algorithm corroborated these findings where close associations were observed between SCA17 and HLD7 and mitochondrial diseases (see interactive figure on www.mitodb.com/network.html or Fig. S3 ). Furthermore, a machine-learning algorithm and a mitochondrialscoring algorithm predicted mitochondrial involvement in SCA17 and HLD7, but not in NAIC, TCOF, or DBA ( Fig. 2 E and F) . Indeed, siRNA knockdown of TBP (mutated in SCA17) or POLR3A (mutated in HLD7) led to changes of mitochondrial membrane potential similar to those observed in CSA and CSB knockdown cells, whereas knockdown of CIRH1A (mutated in NAIC), TCOF1 (mutated in TCOF), or Rps19 (mutated in DBA) did not result in mitochondrial membrane potential alterations (Fig. 2G) . Indeed, TCOF1 has recently been shown to be downstream of rDNA transcription (24) as well as of PARP1 recruitment to rDNA (27) . Notably, the mitochondrial membrane potential changes associated with TBP or POLR3A knockdown were not observed in PARP1-null cells (Fig. 2G) . In support of the observation that general translation defects did not lead to mitochondrial changes, inhibition of translation by treatment with cycloheximide did not result in a mitochondrial phenotype (Fig.  S2 E and F) . Likewise, only modest changes in translation rates were seen by measuring incorporation of 35 S-labeled methionine and cysteine and by assessing polysome profiles in CSA-or CSB-deficient SH-SY5Y cells as well as in SH-SY5Y cells treated with transcriptional inhibitors (Fig. S2 G and H) . In summary, loss of rDNA transcription, but not translation, leads to mitochondrial dysfunction in Cockayne syndrome, and a mitochondrial etiology mediated by PARP1 may underlie the pathology observed in SCA17 and HLD7.
Loss of CSA or CSB Leads to Transcriptional Stalling at Non-B DNA Because inhibition or loss of PARP1 attenuated the mitochondrial phenotype caused by defective rDNA transcription, we asked if PARP1 might be activated in the nucleolus of cells with reduced CSA or CSB. Using immunocytochemistry, we found increased levels of poly-ADP ribose (PAR) in the nucleolus (marked by nucleolin) of cells deficient in CSA or CSB (Fig. 3A) . Notably, nucleolin levels appeared to be increased in the CSA-or CSBdeficient cells (Fig. 3A) . Nucleolin binds DNA secondary structures such as G4 structures (28), and these structures have been proposed to activate PARP1 (29, 30) . We therefore asked if CSA-or CSB-deficient SH-SY5Y cells might show defects in transcription through G4 DNA sequences or other DNA secondary structures. Toward this aim, we performed RNA sequencing (RNA-seq) to determine whether certain DNA regions might influence the transcription efficiency in CSA-or CSB-deficient cells. Aligned reads were normalized to the control to minimize possible sequencing artifacts. After alignment, we developed a custom script to look at the normalized RNA-seq coverage in the 400 nucleotides preceding and following predicted DNA secondary structures in the genome. Inverted-, direct-, or mirror repeats, z-DNA sequences, or short tandem repeats only led to minor pausing of the RNA polymerase in the CSA-or CSB-deficient cells, and there was, as expected, no strand bias, whereas A-phased repeats in the nontranscribed strand led to moderate stalling (Fig. S4) . However, the strongest stalling of the polymerase was seen with G4-forming sequences as evidenced by increased coverage approaching the G4 structure. Loss of coverage was observed in the nucleotides around the G4 structure, likely representing alignment artifacts due to the G-rich sequence. Interestingly, polymerase stalling displayed strand bias in the CSA-or CSB-deficient cells, with particularly prominent stalling occurring when the G4 is in the transcribed strand (Fig.  3B) . Furthermore, the amount of stalling depended on the amount of guanines in the sequence and thus the likelihood of the formation of a G4 (Fig. 3B) . Notably, there was no loss of signal downstream of the structures, suggesting that the polymerase eventually makes it through. Obstructive DNA structures might lead to less transcription in the distal compared with proximal part of genes. To test this, we performed nuclear run-on experiments on a few genes that showed altered expression in the microarray experiment. Although loss of transcription elongation was found in CSA-or CSB-deficient SH-SY5Y cells as previously reported (4, 17) , there was no overall loss of transcription when we compared the signal from the 5′ end with the 3′ end of the genes (Fig. S5 A and B) . Furthermore, the RNAseq data did not show loss of transcription in CSA-or CSB-deficient cells relative to the control when investigating loss of coverage as a function of gene size across the entire transcriptome (Fig. S5C) . In addition, we did not find a generalized change in mitochondrial transcription rates in CSA-or CSB-deficient cells that could explain alterations in mitochondrial function (Fig. S5D) .
We next studied whether changes in transcription through G4 quadruplex structures are involved in normal aging by analyzing a published RNA-seq dataset of cells harvested from the iliac crest of young and elderly women (Gene Expression Omnibus accession no. GSE72815). Although we found strand bias and transcriptional pausing at G4 sequences, we did not find increased pausing with aging (Fig. S6A) . However, we did find increased variability in transcriptional rates with age around G4 regions, perhaps suggesting alterations in the way G4 structures are handled (Fig. S6A) . If G4 structures have to be resolved for transcription to occur, one would expect that regions that show less transcription would have more stalling compared with highly transcribed regions. Indeed, that appears to be the case in vivo when we measured the amount of stalling as a function of coverage in the G4-containing region. Here we found that regions with low coverage have greater stalling than regions with high coverage, and this effect is only seen when the G4 is on the transcribed strand (Fig. S6B) . In summary, transcriptional stalling occurs at DNA secondary structures, and there appears to be transcription-coupled resolution of DNA secondary structures involving CSA and CSB.
CSB Is Able to Resolve G4 Structures
Because CSB contains a helicase domain and is able to anneal cDNA strands, we asked whether recombinant CSB can resolve G4 structures and thereby facilitate transcription through them. We found that CSB is unable to unwind bimolecular and tetramolecular G4s (Fig. S7 A-C) . However, unimolecular G4s that contained either a 3′ or a 5′ oligonucleotide tail were efficiently melted by CSB in the presence of cDNA, leading to annealing of the two oligonucleotides (Fig. 3 C and D and Fig. S7D ). This activity was independent of ATP hydrolysis because the reaction occurred equally efficiently with or without ATP. The annealing activity of CSB was contingent upon either a 3′ or a 5′ tail because CSB was unable to anneal the G4 structure with a peptide nucleic acid complementary to only the G4 sequence. FANCJ, a known G4 DNA helicase, however, was able to resolve this structure (Fig. S7E) . Because CSB appeared to be independently able to melt G4 structures, we asked if we could rescue mitochondrial features in CSA-deficient CS3BE cells by overexpressing CSB targeted to the nucleolus (Fig. S8A) . Indeed, that appeared to be the case, as assessed by mitochondrial membrane potential, ROS production, and oxygen consumption rates (Fig. 3 E and F and Fig. S8B) . Interestingly, only CSA overexpression and not CSB was able to rescue UV sensitivity in CS3BE cells, suggesting a decoupling between UV sensitivity and mitochondrial phenotypes as recently also suggested from clinical data (31) (Fig. 3G) .
Stabilization of G4 Structures Leads to Accelerated Aging
We next asked if rDNA G4 structures could activate PARP1. Indeed, recombinant PARP1 was activated by single-stranded rDNA and rRNA that contained G4-forming sequences whereas the complementary controls did not activate PARP1 (Fig. S9A) . To avoid the confounding effects of G4 stabilization on replication, we performed a number of experiments on primary, fully differentiated, nondividing rat cortical neurons. Treatment of these cells with the G4-stabilizing drug pyridostatin or the RNA polymerase I inhibitor CX5461 led to PARP1 activation (Fig. 4A) . Notably, treatment with these drugs did not lead to histone H2AX phosphorylation, suggesting that strand breaks are not driving the activation of PARP1 (Fig. 4A) .
PARP1 activation may lead to loss of NAD + and increased nicotinamide (NAM). We therefore measured the levels of these metabolites in the neurons treated with CX5461 or pyridostatin and found a significant decrease in NAD + /NADH and a trend to increased NAM (Fig. 4 B and C) . Loss of NAD + will lead to increased shunting of pyruvate to lactate. Consistently, by investigating oxygen consumption (OCR) and extracellular acidification (ECAR), we found loss of OCR/ECAR ratios in primary neurons treated with CX5461, pyridostatin, or another G4 stabilizer, TMPYP4, and these changes were rescued by treatment with the PARP1 inhibitor PJ34 (Fig. 4D and raw data in Fig. S9 B and C) . In addition, treatment of neurons with pyridostatin led to a dose-dependent increase in mitochondrial membrane potential (Fig. S9D) . Furthermore, treatment of HeLa cells with pyridostatin or CX5461 led to a similar mitochondrial profile as observed in CSA-or CSB-deficient cells, and this effect was nonadditive (Fig. 4E and Fig. S9 E-G) . In addition, pyridostatin treatment led to loss of rDNA transcription as evidenced by decreased levels of 47S rRNA (Fig. 4F) .
To further understand if defects in transcription through DNA secondary structures could lead to accelerated aging, we treated C. elegans (the somatic cells of which are all postmitotic) with pyridostatin as well as with the rDNA transcriptional inhibitor CX-5461. These treatments led to decreased pharyngeal pumping, loss of mobility, and shortened life span, all hallmarks of accelerated aging (Fig. 4 G-I) . Accelerated aging was also found when using a machine classifier to quantify morphological changes that occur with aging in the head of nematodes (32) (33) (34) (Fig. 4J) . Strikingly, the accelerated aging changes could be rescued by treatment with the NAD + -precursor nicotinamide riboside (NR), although at higher pyridostatin or CX5461 concentrations lifespan shortening could not be rescued (Fig. 4 G-J and Fig. S9H ). In summary, our results suggest that loss of transcription-coupled resolution of DNA secondary structures leads to accelerated aging through G4 formation, PARP1 activation, NAD + depletion, and mitochondrial dysfunction. Discussion PARP1 activity increases with normal aging and in accelerated aging diseases, such as xeroderma pigmentosum group A, ATM, and Cockayne syndrome (8, 11) . We present evidence that PARP1 activation in Cockayne syndrome is caused by stalled transcription at DNA secondary structures that are enriched in rDNA. Using in silico and in vivo techniques, we find that transcription per se rather than downstream translational defects lead to mitochondrial pathology, a conclusion partly based on the discovery of mitochondrial dysfunction in the diseases hypomyelinating leukodystrophy 7 and spinocerebellar ataxia 17. Interestingly, the observed mitochondrial changes with increased mitochondrial membrane potential and oxygen consumption suggest that the changes are not caused by primary mitochondrial dysfunction but rather by a secondary compensatory response due to nuclear changes, as proposed previously (35, 36) . This is in agreement with a number of previous studies showing similar mitochondrial changes as a response to nuclear DNA damage whereas studies in nonisogenic cell lines in the context of Cockayne syndrome have been inconclusive (7, 10, (37) (38) (39) (40) (41) . Notably, G4-forming DNA sequences, which are abundant in rDNA, appear to be potent obstacles to transcription in CSA-or CSB-deficient cells, and these structures activate PARP1 in vitro and in vivo. Recombinant CSB is able to resolve G4-forming DNA structures through an ATP-independent DNA-annealing event, supporting the hypothesis that an accumulation of irresolvable G4 structures in Cockayne syndrome underlies the PARP1 activation in this disease. Finally, accelerated aging caused by G4 stabilization in nematodes can be rescued through replenishment of the central bioenergetics molecule NAD + . Although we believe that the most likely explanation for PARP1 activation is through direct activation by G4 structures, alternatively, PARP1 activation could occur through signaling from posttranslational modification of the stalled RNA polymerase or from other chromatin-associated proteins. Combined, our findings suggest an explanation for the PARP1 activation and mitochondrial alterations observed in Cockayne syndrome (Fig. S9I) .
Previous findings implicate both CSA and CSB in rDNA transcription. Our data support this hypothesis and further underscore the role of rDNA in the aging process (15, 16, 18) . Indeed, an expansion of extrachromosomal rDNA circles (ERCs) were among the first proposed causes of aging in eukaryotes (42) . Although ERC accumulation appears to be an age-associated phenomenon particular to yeast, recent data have shown increased rDNA content in the brains of patients suffering from of Alzheimer's disease or Lewy body dementia (43, 44) . Notably, PARP1 is activated in these diseases (45, 46) . Perhaps age-associated PARP1 activation and NAD + depletion could be caused by rDNA accumulation leading to loss of activity of NAD + -dependent enzymes, such as sirtuins, and consequent mitochondrial dysfunction.
G4 structures have been implicated in both replication and transcription regulation (47) (48) (49) (50) . Here we provide in vivo evidence for transcriptional pausing at DNA sequences that can form G4 structures. In Cockayne syndrome cells, this pausing is exacerbated, leading to mitochondrial dysfunction. Although our study shows that CSB can biochemically resolve G4 structures, the role of CSA in this process is unknown. CSA is part of the DDB1-Cul4-Rbx complex that is involved in ubiquitination of various substrates. It is possible that CSA ubiquitinates proteins involved in the stabilization or resolution of G4 structures. Loss of CSA could thus lead to accumulation of G4 structures and subsequent PARP1 activation.
G4 structures occur at a high frequency in G-rich regions such as the rDNA loci; however, this particular DNA structure is also observed in a number of other regions in the genome. It is possible that the effect that we see when inhibiting RNA polymerase I is due to the large amount of G4 structures in this region, and it is also possible that there are other properties inherently different about the rDNA. Indeed, inhibition of RNA polymerase II also leads to changes in mitochondrial function although these changes are much smaller than observed after RNA polymerase I inhibition. Notably, although we find transcriptional pausing at G4 structures in cells from normal humans, aging does not exacerbate this pausing. This observation suggests that a possible PARP1 activation in normal aging does not depend on decreased transcription-coupled resolution of DNA secondary structures.
In conclusion, this work represents a mechanistic explanation for the pathogenesis of Cockayne syndrome through a convergence of the CSA and CSB pathways and describes a role of transcription-coupled resolution of secondary DNA structures.
Materials and Methods
All cell culture and nematode work was performed according to standard procedures. Western blot, RT-PCR, flow cytometry, Seahorse XF analyses, and nuclear run-ons were performed according to standard procedures. In silico analyses of diseases was done as previously described (26) using the prevalence of clinical features in each disease. RNA-seq was performed by the National Cancer Institute sequencing core. DNA helicase and DNA-annealing assays were done with gel-purified oligonucleotides purchased from Lofstrand Labs. 
